286 related articles for article (PubMed ID: 15880245)
1. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
[TBL] [Abstract][Full Text] [Related]
2. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
3. [Histochemical diagnosis of short segment Barrett's esophagus].
Fujiyama Y; Ishizuka I; Koyama S
Nihon Rinsho; 2005 Aug; 63(8):1420-6. PubMed ID: 16101233
[TBL] [Abstract][Full Text] [Related]
4. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
5. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
6. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
7. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
8. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical expression of the p53 and Ki-67 proteins in Barrett's esophagus in Korea].
Kim CW; Lee BI; Kim BW; Kim JI; Park SH; Kim JK; Han SW; Jung IS; Sun HS; Lee AW; Lee KY
Korean J Gastroenterol; 2005 Sep; 46(3):189-95. PubMed ID: 16179838
[TBL] [Abstract][Full Text] [Related]
10. Non-goblet cell population of Barrett's esophagus: an immunohistochemical demonstration of intestinal differentiation.
Chaves P; Cardoso P; de Almeida JC; Pereira AD; Leitao CN; Soares J
Hum Pathol; 1999 Nov; 30(11):1291-5. PubMed ID: 10571507
[TBL] [Abstract][Full Text] [Related]
11. Short segment Barrett's esophagus and distal gastric intestinal metaplasia.
Dietz J; Chaves-E-Silva S; Meurer L; Sekine S; de Souza AR; Meine GC
Arq Gastroenterol; 2006; 43(2):117-20. PubMed ID: 17119666
[TBL] [Abstract][Full Text] [Related]
12. P53 and Ki-67 overexpression in gastroesophageal reflux disease--Barrett's esophagus and adenocarcinoma sequence.
Binato M; Gurski RR; Fagundes RB; Meurer L; Edelweiss MI
Dis Esophagus; 2009; 22(7):588-95. PubMed ID: 19302208
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and COX2 expressions using chromoendoscopical examination.
Çoban Ş; Örmeci N; Savaş B; Ekiz F; Ensari A; Kuzu I; Palabıyıkoğlu M
Dis Esophagus; 2013; 26(2):189-96. PubMed ID: 22591041
[TBL] [Abstract][Full Text] [Related]
14. Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).
Trakál E; Guidi A; Butti AL; Trakál JJ; Sambuelli R; Zárate FE
Acta Gastroenterol Latinoam; 2010 Sep; 40(3):211-5. PubMed ID: 21049770
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
16. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.
Wang DH; Clemons NJ; Miyashita T; Dupuy AJ; Zhang W; Szczepny A; Corcoran-Schwartz IM; Wilburn DL; Montgomery EA; Wang JS; Jenkins NA; Copeland NA; Harmon JW; Phillips WA; Watkins DN
Gastroenterology; 2010 May; 138(5):1810-22. PubMed ID: 20138038
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ
J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029
[TBL] [Abstract][Full Text] [Related]
19. CDX2, COX2 and MUC2 expressions in Barrett's esophagus: can they be useful in determination of the dysplasia?
Türkmen IÇ; Başsüllü N; Uraz S; Yerdel MA; Memışoğlu R; Bülbül Doğusoy G
Turk Patoloji Derg; 2012; 28(3):251-8. PubMed ID: 23011828
[TBL] [Abstract][Full Text] [Related]
20. Is Barrett's metaplasia the source of adenocarcinomas of the cardia?
Clark GW; Smyrk TC; Burdiles P; Hoeft SF; Peters JH; Kiyabu M; Hinder RA; Bremner CG; DeMeester TR
Arch Surg; 1994 Jun; 129(6):609-14. PubMed ID: 8204035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
